REG - Diaceutics PLC - Change of Auditor

DiaceuticsAnnouncement

29/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221129:nRSc8460Ha&default-theme=true

RNS Number : 8460H  Diaceutics PLC  29 November 2022

 

29 November 2022

Diaceutics PLC

("Diaceutics" or "the Company")

 

Change of Auditor

 

Diaceutics PLC (https://www.diaceutics.com/) , (AIM: DXRX), a leading
diagnostic commercialisation company which provides data, analytics and
technology enabled services via its proprietary DXRX platform to the Precision
Medicine market announces that, following the conclusion of a formal tender
process led by the Company's Audit Committee, the Board has approved the
proposed appointment of Ernst & Young ("EY") as the Company's auditor for
the financial year ending 31 December 2022. A proposal to re-appoint EY will
be subject to approval by the Company's shareholders at the next Annual
General Meeting to be held in 2023.

 

PricewaterhouseCoopers LLP, the Company's current auditor, has resigned and
has confirmed that there are no matters connected with it ceasing to hold
office that should be brought to the attention of the members or creditors of
the Company.

 

 

 

Enquiries:

 Diaceutics PLC
 Nick Roberts, Chief Financial Officer                Via Alma PR

 Stifel Nicolaus Europe Limited (Nomad & Broker)      Tel: +44 (0)20 7710 7600
 Ben Maddison
 Stewart Wallace
 Nick Adams

 Alma PR                                              Tel: +44(0)20 3405 0205
 Caroline Forde                                       diaceutics@almapr.co.uk
 Kieran Breheny
 Matthew Young

About Diaceutics

 

At Diaceutics we believe that every patient should have access to the right
treatment at the right time. We provide the world's leading pharmaceutical
companies with an end-to-end solution for the launch of precision medicine
diagnostics enabled by DXRX - The Diagnostic Network®.

 

DXRX is the world's first diagnostic commercialisation platform for precision
medicine, integrating multiple pipelines of real-world diagnostic testing data
from a global network of laboratories.

 

Diaceutics' data capability is one of the three key value drivers it has
integrated into its unique DXRX platform alongside its global Lab network and
product suite tailored for Precision testing.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  APPBKFBKCBDDQDB